DiscoverNeurology MinuteSex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis - Part 1
Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis - Part 1

Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis - Part 1

Update: 2025-11-07
Share

Description

In part one of this two-part series, Dr. Stacey Clardy and Dr. Sandra Vukusic discuss what disease-modifying therapies can be safely continued and strategically timed when pregnancy is anticipated. 

Show citation:

Gavoille A, Leray E, Marignier R, et al. Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis. Neurology. 105(4) e213907. doi:10.1212/WNL.0000000000213907 

Comments 
In Channel
Primary Progressive Aphasia - Part 3

Primary Progressive Aphasia - Part 3

2025-12-0101:41

Screening for Congenital Myasthenic Syndromes in Adults With Seronegative MG

Screening for Congenital Myasthenic Syndromes in Adults With Seronegative MG

2025-11-2802:11

Executive Function Deficits in Genetic Frontotemporal Dementia

Executive Function Deficits in Genetic Frontotemporal Dementia

2025-11-2701:45

Primary Progressive Aphasia - Part 2

Primary Progressive Aphasia - Part 2

2025-11-2601:23

Primary Progressive Aphasia - Part 1

Primary Progressive Aphasia - Part 1

2025-11-2502:08

Women History Minute - Sylvia Lawry

Women History Minute - Sylvia Lawry

2025-11-2405:18

Dementia with Lewy Bodies and Parkinson Disease Dementia

Dementia with Lewy Bodies and Parkinson Disease Dementia

2025-11-2102:11

Outcomes After RCVS With Convexity Subarachnoid Hemorrhage

Outcomes After RCVS With Convexity Subarachnoid Hemorrhage

2025-11-2003:32

November President Spotlight: Medicare 2026 Rulemaking

November President Spotlight: Medicare 2026 Rulemaking

2025-11-1904:09

Safety and Efficacy of Nipocalimab in Adults With Generalized Myasthenia Gravis (Vivacity-MG3)

Safety and Efficacy of Nipocalimab in Adults With Generalized Myasthenia Gravis (Vivacity-MG3)

2025-11-1803:05

Interpreting Cerebrospinal Fluid in the 2024 McDonald Criteria Revisions

Interpreting Cerebrospinal Fluid in the 2024 McDonald Criteria Revisions

2025-11-1702:27

Women History Minute - Marcelle Lapicque

Women History Minute - Marcelle Lapicque

2025-11-1404:14

Super Refractory Status Epilepticus Diagnosis, Management, and Prognostication

Super Refractory Status Epilepticus Diagnosis, Management, and Prognostication

2025-11-1304:38

Prodromal Phase of Migraine - Part 2

Prodromal Phase of Migraine - Part 2

2025-11-1202:56

Prodromal Phase of Migraine - Part 1

Prodromal Phase of Migraine - Part 1

2025-11-1103:01

Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis - Part 2

Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis - Part 2

2025-11-1002:16

Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis - Part 1

Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis - Part 1

2025-11-0704:05

Neurotoxicity Imaging in Children and Young Adults After CAR T-Cell Therapy for B-Cell Malignancies

Neurotoxicity Imaging in Children and Young Adults After CAR T-Cell Therapy for B-Cell Malignancies

2025-11-0604:04

Optic Nerve Inclusion in the 2024 McDonald Criteria Revisions – Part 3

Optic Nerve Inclusion in the 2024 McDonald Criteria Revisions – Part 3

2025-11-0504:00

Optic Nerve Inclusion in the 2024 McDonald Criteria Revisions – Part 2

Optic Nerve Inclusion in the 2024 McDonald Criteria Revisions – Part 2

2025-11-0403:47

loading
Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis - Part 1

Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis - Part 1

American Academy of Neurology